Search Result

Results for "

L1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Akt (2) AMPK (6) Amylases (1) Antibiotic (1) Apolipoprotein (2) Apoptosis (18) Aryl Hydrocarbon Receptor (1) Autophagy (3) Bacterial (6) Bcl-2 Family (4) Beta-lactamase (2) Beta-secretase (2) Biochemical Assay Reagents (2) c-Myc (2) Cannabinoid Receptor (1) Caspase (2) CaSR (1) CD19 (1) CD73 (1) CDK (1) Cholinesterase (ChE) (2) COX (2) Cytochrome P450 (4) Deubiquitinase (5) DGK (1) DNA Stain (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (3) Endogenous Metabolite (1) Endonuclease (1) Epigenetic Reader Domain (1) Eukaryotic Initiation Factor (eIF) (1) Fatty Acid Synthase (FASN) (1) Free Fatty Acid Receptor (1) Fungal (3) Glucosidase (1) GPR109A (1) GSK-3 (1) HBV (3) HDAC (5) HIF/HIF Prolyl-Hydroxylase (4) Histone Demethylase (3) HPV (1) HSP (3) IFNAR (1) IKK (1) Integrin (1) Interleukin Related (1) LAG-3 (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (5) MAP4K (2) MMP (2) MNK (2) Monoamine Oxidase (3) NAMPT (1) NF-κB (2) NOD-like Receptor (NLR) (1) p38 MAPK (2) PARP (2) PD-1/PD-L1 (174) PDK-1 (1) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (1) PKC (1) PPAR (8) PROTAC Linkers (3) PROTACs (3) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (2) RAR/RXR (1) Reactive Oxygen Species (4) RSV (1) Ser/Thr Protease (1) Sirtuin (1) Small Interfering RNA (siRNA) (60) Src (1) STAT (6) STING (1) Target Protein Ligand-Linker Conjugates (2) TGF-β Receptor (1) TNF Receptor (3) Toll-like Receptor (TLR) (6) Tryptophan Hydroxylase (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (213) Cardiovascular Disease (1) Infection (20) Inflammation/Immunology (69) Metabolic Disease (34) Neurological Disease (6)
Click Chemistry:	Azide (1)
Oligonucleotides:	Pre-designed siRNA Sets (60) siRNAs (60)

342

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

116

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124379

TPCK 1 Publications Verification L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK	Ser/Thr Protease HPV Apoptosis PDK-1	Infection Neurological Disease Inflammation/Immunology Cancer
TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the *PDK1/Akt* pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats ^[1] .

HY-149830

PD-L1-IN-2	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting *PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1*-IN-2 is used for colorectal cancer research ^[1].

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit *PD-L1* and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research ^[1].

HY-150202

L1-PEG2-TATE	Others	Others
L1-PEG2-TATE is a nonadentate ligand. L1-PEG2-TATE can be used for the research of imaging ^[1].

HY-W012846A

L-Threitol L-1,2,3,4-Butanetetrol	Biochemical Assay Reagents	Others
L-Threitol is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-RS07481

L1CAM Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
L1CAM Human Pre-designed siRNA Set A contains three designed siRNAs for L1CAM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

L1CAM Human Pre-designed siRNA Set A L1CAM Human Pre-designed siRNA Set A

HY-RS07482

L1TD1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
L1TD1 Human Pre-designed siRNA Set A contains three designed siRNAs for L1TD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

L1TD1 Human Pre-designed siRNA Set A L1TD1 Human Pre-designed siRNA Set A

HY-I0422

L-Porretine L-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid	Biochemical Assay Reagents	Others
L-Porretine is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-N7825

Gomisin L1	Others	Cancer
Gomisin L1 is a lignan, shows inhibitory effect on cell viability of A2780 and Ishikawa cells, with IC₅₀s of 39.06 μM and 74.16 μM, respectively ^[1].

HY-163958

PD-L1-IN-7	PD-1/PD-L1	Cancer
PD-L1-IN-7 (compound CB31) is an inhibitor of *PD-L1, which can induce PD-L1 internalization and PD-L1 retention in cells. PD-L1-IN-7 can inhibit the interaction of PD-1/PD-L1 (IC₅₀: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1*-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells ^[1].

HY-139781

PD-L1-IN-1	PD-1/PD-L1	Cancer
PD-L1-IN-1 is a potent *PD-L1* inhibitor with an IC₅₀ of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells ^[1].

HY-162356

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

HY-P2564

Human PD-L1 inhibitor III	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-P9919A

Durvalumab (anti-PD-L1) 5 Publications Verification MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity ^[1] .

HY-162357

PD-L1-IN-5	PD-1/PD-L1	Cancer
PD-L1-IN-5 (X22) is an orally active *PD-L1* inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo ^[1].

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity ^[1].

HY-162973

PD-L1 ligand 1	PD-1/PD-L1 Ligands for Target Protein for PROTAC	Cancer
PD-L1 ligand 1 is a PROTAC target protein ligand. PD-L1 ligand 1 can be used as a *PD-L1* degrader ^[1].

HY-157811

PD-1/PD-L1-IN-40	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer ^[1].

HY-168080

PD-1/PD-L1-IN-51	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-51 (Compound III-4) is a *PD-1/PD-L1* inhibitor (IC₅₀: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity ^[1].

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-162399

PD-L1-IN-6	PD-1/PD-L1 STAT	Inflammation/Immunology
PD-L1-IN-6 (Compound 16) is an orally active inhibitor for *PD-L1* expression in neutrophil by targeting STAT3 with K_D of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse ^[1].

HY-163757

PROTAC PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC PD-L1 degrader-1 is a CRBN-based *PD-L1-PROTAC* degrader with a notable PD-L1 protein degradation capability. PROTAC PD-L1 degrader-1 shows potent PD-L1 degradation in 4T1 cells with a DC₅₀ of 0.609 μM. PROTAC PD-L1 degrader-1 can be used for the study of breast cancer. (Blue: CRBN ligand (HY-150839), Black: linker; Pink: PD-L inhibitor (HY-19745)) ^[1].

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P2470

Human PD-L1 inhibitor II	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

HY-P2474

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1*/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice ^[1].

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-144447

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

HY-145770

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-163307

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity ^[1].

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent *PD-1/PD-L1* interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model ^[1].

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) is a fully human *IgG1* anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity ^[1].

HY-P5276

Human membrane-bound PD-L1 polypeptide	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production ^[1].

HY-145772

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145773

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145768

PD-1/PD-L1-IN-18	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC₅₀ of 1.054 μM. Antitumor Activity ^[1].

HY-161677

PD-L1/CD-73-IN-1	PD-1/PD-L1 CD73	Inflammation/Immunology Cancer
PD-L1/CD-73-IN-1 (compound CC-5) is *PD-L1/CD73* inhibitor with IC₅₀ values of 6 nM and 0.773 μM to *PD-L1* and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro ^[1].

HY-159125

PD-1/PD-L1-IN-47	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-47 (MolPort-001-742-690) is a PH-selective *PD-1/PD-L1* signaling pathway inhibitor with significant affinity for PD-L1 under acidic conditions and lower toxicity. PD-1/PD-L1-IN-47 can be used in the study of tumors ^[1].

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner ^[1].

HY-163534

PD-1/PD-L1-IN-43	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and *PD-L1. PD-1*/PD-L1-IN-43 can be used in anti-tumor studies ^[1].

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer ^[1].

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity ^[1].

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy ^[1].

HY-160585

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research ^[1].

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks